Limaca Medical Email Formats

About Limaca Medical

Limaca Medical Ltd. is a privately held company addressing critical challenges in endoscopic biopsy diagnostics for life-threatening pancreatic and other gastroenterological cancers. The procedures with current manual devices are inefficient and have high-skill dependency and the tissue is fragmented and low quality, leading to suboptimal diagnosis. Limaca’s Precision-GI™ device provides high-quality, intact tissue samples in fewer passes, ensuring faster and more accurate diagnosis. Founded in 2017 in collaboration with The Trendlines Group, Rambam Health Care, and the Israel Innovation Authority, Limaca has developed a superior motorized, automated rotational tissue-cutting biopsy device for endoscopic ultrasound-guided (EUS) procedures. Recognized by the FDA with Breakthrough Device Designation (2022) and 510(k) clearance (2023), Precision-GI™ minimizes procedural variability and trauma, delivering consistent and efficient results. Limaca aims to lead the shift in endoscopic biopsy diagnostics, driving the transition from manual technologies to advanced, automated solutions. With Precision-GI™, the company is poised to set a new standard for automated biopsy devices, transforming endoscopic procedures and improving patient outcomes. In addition to its progress with pancreatic biopsies, Limaca is preparing to expand its platform to lung biopsies, addressing a $1B+ global market potential. Backed by a multidisciplinary team and key milestones such as the CMS TPT Payment designation (effective January 2025), Limaca Medical is positioned to redefine biopsy diagnostics globally. For more information please visit our website at: https://limaca-medical.com/

View contact profiles from Limaca Medical